Sofinnova Partners
Sofinnova Partners is one of Europe’s longest-standing life-sciences venture firms.
- Healthcare and biotechnology venture capital investor
- Healthcare & BioTech Venture Capital
- Tier II
Overview
Sofinnova Partners is one of Europe’s longest-standing life-sciences venture firms. Its strategies cover biotechnology, therapeutics, medtech, industrial biotechnology, and related areas in which scientific development and company building are central to value creation.
The firm’s longevity provides experience across clinical, regulatory, financing, and exit cycles. Its European network also helps connect regional science with international management, pharmaceutical partners, specialist investors, and commercialization markets. Within The Economy Wiki, the institution is connected to the Healthcare & Biotechnology Venture Capital market category.
Firm facts
| Institution | Sofinnova Partners |
| Type | Healthcare and biotechnology venture capital investor |
| Headquarters | Paris / London / Milan, France / United Kingdom / Italy |
| Founded | 1972 |
| Primary ranking focus | Healthcare & BioTech Venture Capital |
| Highest 2026 tier | Tier II |
Activities and investment capabilities
Sofinnova Partners operates within life-sciences innovation, clinical development and healthcare company building. Its category-specific capabilities are summarized below.
Life-sciences investing
Capital for therapeutics, diagnostics, medical devices and research platforms.
Clinical development
Support across scientific validation, trials, regulation and commercialization.
Healthcare innovation
Investment in care delivery, health technology and data-enabled medical businesses.
Strategy and market coverage
Stage and strategy coverage
Company formation through growth; translational research; clinical and commercial financing
Sector and market coverage
Biotechnology; therapeutics; diagnostics; medtech; digital health and healthcare services
Market position
Sofinnova fits Tier II because its specialist heritage, institutional continuity, strategy breadth, and importance to the European life-sciences ecosystem make it a leading established healthcare venture firm.
Sofinnova Partners is assessed within the Healthcare & Biotechnology Venture Capital framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
Sofinnova Partners is recognized Tier II in Top 30 Healthcare & BioTech Venture Capital 2026. The rankings compare institutions by market relevance, investment or operating capability, sector and stage expertise, institutional credibility and current activity. Comparable links support navigation and do not imply that every institution competes for every company, fund commitment or transaction.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through the institution’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to Sofinnova Partners as the public-facing organization. Individual funds, management companies, advisers, lending entities, broker-dealers and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Sofinnova Partners |
| Headquarters | Paris / London / Milan, France / United Kingdom / Italy |
| Public website | sofinnovapartners.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the venture, financing, diligence and private-market themes relevant to this institution:
- The Mid-Market Advantage in Healthcare Private Equity
- Growth Equity vs Venture Capital and Buyouts: Key Differences
- Private Equity Technology Due Diligence in the AI Era
